Published in Prev Med on October 08, 2010
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ (2011) 1.23
Does an offer for a free on-line continuing medical education (CME) activity increase physician survey response rate? A randomized trial. BMC Res Notes (2012) 0.86
The Polypill in the prevention of cardiovascular disease. Prev Med (2010) 0.83
Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open (2013) 0.81
Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet. Prev Med (2010) 0.78
The Polypill: From Promise to Pragmatism. PLoS Med (2015) 0.77
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2012) 0.75
Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study. BMJ Open (2016) 0.75
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Sick individuals and sick populations. Int J Epidemiol (1985) 23.44
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10
Primary prevention of cardiovascular disease: time to get more or less personal? JAMA (2009) 1.96
Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 1.89
The geography of stroke mortality in the United States and the concept of a stroke belt. Stroke (1995) 1.57
Has the risk for coronary heart disease changed among U.S. adults? J Am Coll Cardiol (2006) 1.30
Combination pharmacotherapy for cardiovascular disease. Ann Intern Med (2005) 1.14
The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. J Med Screen (2004) 1.13
National Cholesterol Education Program risk assessment and potential for risk misclassification. Prev Med (2006) 1.09
The polypill concept. Heart (2010) 0.97
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Low health literacy and health outcomes: an updated systematic review. Ann Intern Med (2011) 16.08
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2003) 5.93
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2009) 4.90
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol (2011) 4.61
Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2003) 4.55
Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2014) 4.45
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care (2007) 3.62
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (2008) 3.56
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 3.41
Promoting informed choice: transforming health care to dispense knowledge for decision making. Ann Intern Med (2005) 3.34
Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2004) 3.26
Health literacy interventions and outcomes: an updated systematic review. Evid Rep Technol Assess (Full Rep) (2011) 3.24
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med (2004) 3.06
Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2002) 3.05
Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med (2007) 3.03
Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation (2008) 2.85
Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Intern Med (2010) 2.82
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 2.64
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Reconsidering the approach to prevention recommendations for older adults. Ann Intern Med (2010) 2.48
Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc (2013) 2.47
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Screening for asymptomatic carotid artery stenosis: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2014) 2.41
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 2.41
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 2.41
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40
COX-2 inhibitors--lessons in drug safety. N Engl J Med (2005) 2.39
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Recent trials in hypertension: compelling science or commercial speech? JAMA (2006) 2.30
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes (2011) 2.29
The safety risks of innovation: the FDA's Expedited Drug Development Pathway. JAMA (2012) 2.28
Global risk of coronary heart disease: assessment and application. Am Fam Physician (2010) 2.21
A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol (2011) 2.19
ALLHAT: setting the record straight. Ann Intern Med (2004) 2.19
From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol (2004) 2.16
Differences in medical care and disease outcomes among black and white women with heart disease. Circulation (2003) 2.16
Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ (2013) 2.06
The necessity for clinical reasoning in the era of evidence-based medicine. Mayo Clin Proc (2013) 2.06
US academic drug discovery. Nat Rev Drug Discov (2011) 2.06
Lead editorial: trials - using the opportunities of electronic publishing to improve the reporting of randomised trials. Trials (2006) 1.98
Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (2010) 1.95
Age as a modifiable risk factor for cardiovascular disease. Lancet (2008) 1.94
European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation (2010) 1.90
Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke (2011) 1.86
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA (2004) 1.85
Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension (2006) 1.82
Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med (2013) 1.74
Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol (2012) 1.71
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 1.67
Screening for carotid artery stenosis: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2007) 1.66
Suicidal behavior and depression in smoking cessation treatments. PLoS One (2011) 1.65
Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm (2011) 1.64
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ (2009) 1.63
The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med (2007) 1.60
Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA (2004) 1.60
Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother (2010) 1.59
Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Services Task Force. Obstet Gynecol (2003) 1.59
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ (2010) 1.58
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57
Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med (2002) 1.56
Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc (2005) 1.54
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study. Ann Intern Med (2016) 1.54
Genome-wide association studies of the PR interval in African Americans. PLoS Genet (2011) 1.53
Why guideline-making requires reform. JAMA (2009) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol (2010) 1.51
Parecoxib, valdecoxib, and cardiovascular risk. Circulation (2005) 1.51
Natural history of the early repolarization pattern in a biracial cohort: CARDIA (Coronary Artery Risk Development in Young Adults) Study. J Am Coll Cardiol (2013) 1.50
Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke (2010) 1.48
Comparison of the prognostic significance of the electrocardiographic QRS/T angles in predicting incident coronary heart disease and total mortality (from the atherosclerosis risk in communities study). Am J Cardiol (2007) 1.48
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol (2010) 1.47
Tiotropium and the risk of death in COPD. N Engl J Med (2014) 1.46
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension (2011) 1.46